Compare
Teleflex Inc vs ICU Medical Inc vs Integra Lifesciences Holdings Corp vs Insulet Corp
| Latest fiscal year | Teleflex Inc TFX | ICU Medical Inc ICUI | Integra Lifesciences Holdings Corp IART | Insulet Corp PODD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.99B | $2.23B | $1.64B | $2.71B |
| Revenue growth (YoY) | +17.2% | -6.3% | +1.5% | +30.7% |
| Gross margin | 56.2% | 36.8% | 50.9% (computed) | 71.6% |
| Operating margin | 5.9% | 1.9% | -30.2% | 17.5% |
| Net margin | -45.4% | 0.0% | -31.6% | 9.1% |
| Net income | -$905.64M | $732.0K | -$516.47M | $247.10M |
| EPS (Diluted) | -$20.25 | $0.03 | -$6.74 | $3.48 |
| Operating cash flow | $96.68M | $179.85M | $50.38M | $569.30M |
| Free cash flow | $1.45M | $91.80M | -$31.05M | $377.70M |
| Cash & equivalents | $378.56M | n/a | $235.05M | n/a |
| Total assets | $6.95B | $4.05B | $3.60B | $3.19B |
| Total liabilities | $3.82B | n/a | $2.56B | $1.68B |
| Shareholders' equity | $3.12B | $2.12B | $1.04B | $1.52B |
| Return on year-end equity | -29.0% | 0.0% | -49.5% | 16.3% |
| Shares outstanding | n/a | 24.69M | n/a | 70.39M |
Revenue, most recent five fiscal years
| Fiscal year | Teleflex Inc | ICU Medical Inc | Integra Lifesciences Holdings Corp | Insulet Corp |
|---|---|---|---|---|
| Latest | $1.99B Ended 2025-12-31 | $2.23B Ended 2025-12-31 | $1.64B Ended 2025-12-31 | $2.71B Ended 2025-12-31 |
| 1 year earlier | $1.70B Ended 2024-12-31 | $2.38B Ended 2024-12-31 | $1.61B Ended 2024-12-31 | $2.07B Ended 2024-12-31 |
| 2 years earlier | $1.71B Ended 2023-12-31 | $2.26B Ended 2023-12-31 | $1.54B Ended 2023-12-31 | $1.70B Ended 2023-12-31 |
| 3 years earlier | $2.79B Ended 2022-12-31 | $2.28B Ended 2022-12-31 | $1.56B Ended 2022-12-31 | $1.31B Ended 2022-12-31 |
| 4 years earlier | $2.81B Ended 2021-12-31 | $1.32B Ended 2021-12-31 | $1.54B Ended 2021-12-31 | $1.10B Ended 2021-12-31 |